This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Bruker (BRKR) Assay to Offer Reliable Omicron Variant Detection
by Zacks Equity Research
Bruker's (BRKR) FluoroType SARS-CoV-2 varID Q assay is anticipated to provide reliable detection of the novel Omicron (B.1.1.529) variant of SARS-CoV-2.
Abbott (ABT) Nutrition Sales Strong Amid Spike in COVID Cases
by Zacks Equity Research
Abbott (ABT) is registering strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
NEOGEN (NEOG) Strengthens Global Foothold With Delf Buyout
by Zacks Equity Research
NEOGEN (NEOG) management believes that Delf's 40 years of experience in the UK dairy hygiene market will help it strengthen its foothold in this region's dairy chemicals market.
Walgreens Boots (WBA) Faces Margin Pressure, Solvency Issue
by Zacks Equity Research
Of late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' (WBA) margin significantly.
Henry Schein (HSIC) Introduces Treatment Planning Software
by Zacks Equity Research
The Studio Pro 4.0 launched by Henry Schein's (HSIC) orthodontics business will enable Reveal Clear Aligners providers to personalize treatment plans with greater ease and control.
Medtronic (MDT) Gets Health Canada License for GI Genius Module
by Zacks Equity Research
Medtronic Canada ULC, a subsidiary of Medtronic (MDT), receives Health Canada license for the GI Genius module that aids in colorectal cancer screening.
Here's Why You Should Invest In Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) better-than-expected results and strong segmental performance.
QIAGEN (QGEN), DiaSorin to Broaden Access to Latent TB Testing
by Zacks Equity Research
QIAGEN (QGEN) and DiaSorin gained FDA approval for their jointly-created LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS platform.
Here's Why You Should Hold on to Globus Medical (GMED) for Now
by Zacks Equity Research
Investors are optimistic about Globus Medical's (GMED) better-than-expected earnings and robust ExcelsiusGPS performance.
Here's Why You Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) given its better-than-expected results and robust SaaS business performance in the fiscal first quarter.
Smith+Nephew (SNN) Introduces Real Intelligence & CORI System
by Zacks Equity Research
Smith+Nephew (SNN) debuts new brand of enabling technology solutions as well as its next-generation handheld robotics platform in Canada.
Quest Diagnostics' (DGX) Base Volumes Rise, Testing Recovers
by Zacks Equity Research
Contributions from new hospital lab management contracts as well as people returning to the healthcare system aid Quest Diagnostics (DGX).
Medtronic (MDT) Gets CE Mark for Radial Artery Access Portfolio
by Zacks Equity Research
Medtronic's (MDT) Rist Radial Access Catheters are indicated for the introduction of interventional devices into the peripheral, coronary and neuro vasculature.
Here's Why You Should Retain Insulet (PODD) Stock for Now
by Zacks Equity Research
Strong domestic and international performance by Omnipod is driving the top line for Insulet (PODD).
CVS Health (CVS) Retail Business Grows Despite Cost Pressure
by Zacks Equity Research
CVS Health's (CVS) retail business sees solid rebound in front-store sales with strength across all categories.
SmileDirectClub (SDC) to Boost Europe Presence, Enter France
by Zacks Equity Research
SmileDirectClub (SDC) since its foray into Europe in 2019 has been seeing remarkable market penetration of its oral care products.
Neogen (NEOG) Q1 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Strong segmental performance and contributions from new acquisitions and product launches drove Neogen's (NEOG) revenues in the first quarter of fiscal 2022.
Boston Scientific (BSX) Strategic Buyouts Aid Amid Cost Woes
by Zacks Equity Research
Boston Scientific (BSX) is optimistic about its recent deal to acquire Israel-based Lumenis that develops and commercializes energy-based medical solutions.
Boston Scientific's (BSX) New Buyout to Aid Clot Management
by Zacks Equity Research
The acquisition of Devoro Medical by Boston Scientific (BSX) is expected to advance the company's core emphasis on clot management.
NEOGEN (NEOG) to Enter Retail Parasiticide Space With New Buyout
by Zacks Equity Research
NEOGEN's (NEOG) acquisition of CAPInnoVet expands its Animal Safety division and offers a strategic entry into the retail parasiticide market.
Quest Diagnostics' (DGX) COVID-19 Test Demand Up in Q3 Months
by Zacks Equity Research
The "Path Out of the Pandemic" plan of the U.S. Government, while emphasizing more on a magnified access for testing, comes as a major breakthrough for Quest Diagnostics (DGX).
Stryker's (SYK) Trauma & Extremities Arm Unveils New Product
by Zacks Equity Research
The newly launched Citrelock Tendon Fixation Device System expands Stryker's (SYK) Foot & Ankle offerings.
Here's Why You Should Retain National Vision (EYE) For Now
by Zacks Equity Research
Investors are optimistic about National Vision (EYE) owing to new store growth and pandemic-induced increase in demand for the company's offerings.
Here's Why You Should Retain Boston Scientific (BSX) for Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) given a strong second-quarter performance and strength in the Structural Heart business.
Quest Diagnostic (DGX) Raises View on COVID-19 Testing Surge
by Zacks Equity Research
Going by the current situation of daily increase in the coronavirus case count, Quest Diagnostics (DGX) expects COVID-19 molecular testing volumes to remain stronger through the rest of the year.